City

Clinical trials near Atlanta, United States

Active studies with a listed research site in Atlanta, United States.

21active studies

10recruiting now

10countries represented

140largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 2

A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes

Obesity, OverweightCondition

Macupatide, EloralintideTreatment

Argentina, Australia42 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT07215559See eligibility →

Recruiting nowNot applicable

Wild Blueberries for Gut, Brain, and Heart Health in Adults With High Blood Pressure

Hypertension (Without Type 2 Diabetes Mellitus), High Blood PressureCondition

Wild Blueberry, PlaceboTreatment

United States1 locations

Georgia State UniversitySponsor

Updated 2026-09-02 · NCT06735599See eligibility →

Recruiting nowNot applicable

Wild Blueberries for Gut, Brain, and Cardiometabolic Health in Prediabetes

Prediabetes (Insulin Resistance, Impaired Glucose Tolerance), FemaleCondition

Wild Blueberry, PlaceboTreatment

United States1 locations

Georgia State UniversitySponsor

Updated 2026-09-02 · NCT06735651See eligibility →

Recruiting nowPhase 3

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Obesity, OverweightCondition

aleniglipron, aleniglipronTreatment

United States74 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-09-01 · NCT07654374See eligibility →

Recruiting nowPhase 2

A Study to Assess the Efficacy, Safety and Tolerability of AT673 Co-administered With Semaglutide in Adult Participants With Type 2 Diabetes (T2D) and Overweight or Obesity

Adults With Overweight/Obesity and Type 2 DiabetesCondition

AT673 low dose, AT673 high doseTreatment

United States8 locations

Antag TherapeuticsSponsor

Updated 2026-09-01 · NCT07724340See eligibility →

Recruiting nowPhase 3

A Study of Orforglipron (LY3502970) in Adolescent Participants With Obesity, or Overweight With Related Comorbidities

Obesity, OverweightCondition

Orforglipron, PlaceboTreatment

Israel, Italy34 locations

Eli Lilly and CompanySponsor

Updated 2026-08-24 · NCT06672939See eligibility →

Recruiting nowPhase 2

Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL

B-cell Acute Lymphoblastic Leukemia, ObesityCondition

IDEAL2 InterventionTreatment

United States16 locations

Etan OrgelSponsor

Updated 2026-08-19 · NCT05082519See eligibility →

Recruiting nowPhase 2

A Study of PF-08653945 and PF-08653944 in Adults With Overweight or Obesity (SOLIS-1)

Overweight, ObesityCondition

PF-08653945, PF-08653944Treatment

Canada, United States65 locations

PfizerSponsor

Updated 2026-08-17 · NCT07575932See eligibility →

Recruiting nowPhase 3

Investigating the Impact of GLP-1 RA Therapy on Osteosarcopenia in Older Female Adults With Diabetes

Diabetes Mellitus, Type 2Condition

SemaglutideTreatment

United States1 locations

Emory UniversitySponsor

Updated 2026-08-03 · NCT07428746See eligibility →

Recruiting nowNot applicable

Ablation Registry (Combined Gastric Mucosal Ablation With Endoscopic Sleeve Gastroplasty for Weight Loss)

ObesityCondition

Combined gastric mucosal ablation with endoscopic sleeve gastroplastyTreatment

United States2 locations

True You Weight LossSponsor

Updated 2024-05-22 · NCT06420700See eligibility →

Opening soonPhase 3

A Research Study Investigating How Well the Medicine Zenagamtide Helps People With Excess Body Weight Lose Weight Compared to Semaglutide

Overweight, ObesityCondition

Zenagamtide, SemaglutideTreatment

United States43 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07668414See eligibility →

Opening soonNot applicable

Evaluation of a Mobile Wellness Application and Wearable Fitness Tracker on Weight Management and Health Outcomes

Obesity & OverweightCondition

App + Fitness Tracker, App OnlyTreatment

United States1 locations

BetterMe LimitedSponsor

Updated 2026-03-11 · NCT07463144See eligibility →

Active, not recruitingPhase 2

Efficacy and Safety of Petrelintide in Participants With Overweight or Obesity and Type 2 Diabetes (ZUPREME 2)

Overweight, Type 2 DiabetesCondition

Petrelintide, PlaceboTreatment

United States48 locations

Zealand PharmaSponsor

Updated 2026-08-21 · NCT06926842See eligibility →

Active, not recruitingNot applicable

Fiber-rich Foods to Treat Obesity and Prevent Colon Cancer

Colon Cancer, ObesityCondition

High Fiber Diet Featuring Legumes (HLD), Healthy American DietTreatment

United States1 locations

Emory UniversitySponsor

Updated 2026-08-20 · NCT04780477See eligibility →

Active, not recruitingNot applicable

NOURISH-T+: Promoting Healthy Eating and Exercise Behaviors

Obesity, Childhood, CancerCondition

NOURISH-T+, Brief NOURISH-T+Treatment

United States10 locations

University of South FloridaSponsor

Updated 2026-08-12 · NCT04656496See eligibility →

Active, not recruitingPhase 2

Specialized Pro-resolving Lipid Mediators and Treatment Resistant Depression

Treatment Resistant Depression, InflammationCondition

Omega 3, PlaceboTreatment

United States3 locations

Massachusetts General HospitalSponsor

Updated 2026-07-01 · NCT05774665See eligibility →

Active, not recruitingPhase 2

MIST (Metabolic Intervention With Semaglutide and THR-β Therapy) Trial

Adult Obesity, Weight ManagementCondition

ECC4703, PlaceboTreatment

United States15 locations

EccogeneSponsor

Updated 2026-06-25 · NCT07505303See eligibility →

Active, not recruitingPhase 3

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Weight LossCondition

VK2735Treatment

Puerto Rico, United States127 locations

Viking Therapeutics, Inc.Sponsor

Updated 2026-04-07 · NCT07104383See eligibility →

Active, not recruitingPhase 4

Effect of Naltrexone Hydrochloride ER and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on Major Adverse Cardiovascular Events (MACE)

ObesityCondition

Naltrexone-Bupropion (NB) Combination, PlaceboTreatment

United States140 locations

Currax PharmaceuticalsSponsor

Updated 2026-03-31 · NCT06098079See eligibility →

Active, not recruitingPhase 2

Study to Evaluate the Effect on Obesity of QW Nimacimab and QW Nimacimab Co-administered With Semaglutide vs Placebo

ObesityCondition

Nimacimab injection, Nimacimab placebo injectionTreatment

United States16 locations

Skye Bioscience, Inc.Sponsor

Updated 2026-01-14 · NCT06577090See eligibility →

Active, not recruitingPhase 3

VK2735 for Weight Management Phase 3

Weight LossCondition

VK2735Treatment

Puerto Rico, United States137 locations

Viking Therapeutics, Inc.Sponsor

Updated 2025-11-24 · NCT07104500See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near Atlanta, United States

Current studies

Related cities